EGFR and non-small cell lung carcinoma: The outcomes of First-SIGNAL, NEJ002 and WJTOG3405 trials [16–18] were same to those of IPASS in NSCLC patients carrying positive EGFR mutation through comparing gefitinib with doublet chemotherapy as first-line therapy.